GLP-1 & Incretin Science
Why Orthopaedic Surgeons Started Paying Attention
Gatto and colleagues reviewed the effects of GLP-1 agonists on musculoskeletal health and orthopaedic care in Current Reviews in Musculoskeletal Medicine in 2025 — a specialty that encounters these compounds through joint disease, surgical planning and perioperative management rather than through metabolic care.
Key facts
- Review
- Gatto 2025 (PMID 40372699)
- Journal
- Curr Rev Musculoskelet Med, October 2025
- Scope
- Musculoskeletal health and orthopaedic care
- Relevance
- Joint load, bone, muscle, perioperative
- Perioperative issue
- Delayed gastric emptying and anaesthesia
- Weight-bearing joints
- Load reduction is mechanical
Why a musculoskeletal specialty has its own view
Orthopaedics encounters obesity constantly — as a driver of joint degeneration, as a factor in surgical risk, and as a determinant of implant outcomes. A drug class producing 15 to 25% weight reduction changes all three at once, which makes it a specialty concern independent of anything metabolic.
Why weight matters mechanically at the knee
The knee experiences forces several times body weight during ordinary walking, because muscle contraction across the joint adds to the load gravity imposes. Reducing body mass therefore reduces joint force by a multiple of the mass lost. That is a mechanical argument, and it does not depend on any effect of the drug beyond the weight change.
Research material referenced
Retatrutide 10mg — third-party HPLC tested
The perioperative question
Delayed gastric emptying means stomach contents may remain longer than fasting guidance assumes, which matters for anaesthesia because it affects aspiration risk. That is a scheduling and assessment problem for surgical teams rather than a pharmacological one, and it arises for any procedure requiring sedation.
The competing considerations for surgery
Weight reduction before joint replacement may improve outcomes and reduce complications. Against that sit the bone and lean mass changes accompanying rapid weight loss, and the perioperative gastric emptying issue. A specialty review is where those are weighed together rather than considered one at a time.
Why this is a different question from the metabolic one
Metabolic medicine asks whether the drug improves glycaemia, cardiovascular risk or organ outcomes. Orthopaedics asks whether a patient is a better surgical candidate afterwards, and whether the tissue being operated on has changed. Those are separate questions and neither literature answers the other's.
What this does not concern
Research material. These are licensed medicines encountered in clinical practice. Nothing supplied on this site is a GLP-1 receptor agonist, is relevant to surgical planning, or has any bearing on the care of any person.
Extended research context
The GLP-1 & Incretin Science deep dive
Deep dive: the two routes to a bigger effect
Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.
Deep dive: why a percentage is not a result
The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.
Deep dive: what happens after the trial stops
Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.
Research applications
- ▸Comparing incretin and amylin compounds on a like-for-like basis
- ▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
- ▸Tracking the obesity pipeline across sponsors and jurisdictions
- ▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
- ▸Distinguishing licensed medicines from investigational compounds
Handling checklist
- ✓Identify which estimand a quoted percentage comes from before citing it
- ✓Check the trial population and baseline BMI against the comparison you are making
- ✓Confirm the duration and whether the reduction curve had plateaued
- ✓Read discontinuation rates alongside efficacy figures
- ✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Comparing headline percentages across different trials
Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.
✗ Quoting the larger of two figures from the same trial
Fix: Name the estimand. Efficacy and treatment-policy answer different questions.
✗ Treating peak reduction as a durable outcome
Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.
✗ Assuming an oral route means a weaker mechanism
Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.
✗ Reading investigational compounds as available treatments
Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Which weight-loss compound produces the largest reduction?
- What is the difference between CagriSema and amycretin?
- What is an amylin receptor agonist?
- How much weight is regained after stopping a GLP-1?
- Why does CagriSema report two different percentages?
- Why is orforglipron less effective than retatrutide?
Frequently asked questions
- Why do orthopaedic specialists care about GLP-1 drugs?
- Obesity drives joint degeneration, surgical risk and implant outcomes. A drug producing 15–25% weight reduction changes all three.
- How much does weight loss reduce knee load?
- By a multiple of the mass lost, because the knee experiences forces several times body weight during walking as muscle contraction adds to gravitational load.
- What is the perioperative concern?
- Delayed gastric emptying means stomach contents may persist beyond what fasting guidance assumes, which affects aspiration risk under anaesthesia.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedGatto A et al., The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care — Curr Rev Musculoskelet Med 2025 (PMID 40372699)pubmed.ncbi.nlm.nih.gov
- PubMedBliddal H et al., Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis — NEJM 2024 (PMID 39476339)pubmed.ncbi.nlm.nih.gov
- PubMedAnastasilakis AD et al. — Diabetes Obes Metab 2025 (PMID 40555693)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066) — Retatrutide pivotal obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268) — Maintenance of weight reductionclinicaltrials.gov
- RefNovo Nordisk · CagriSema REDEFINE 1, published in NEJMprnewswire.com
- PubMedAmycretin phase 1b/2a subcutaneous study — PubMed (PMID 40550231)pubmed.ncbi.nlm.nih.gov
- RefTrajectory of weight regain after GLP-1 cessation — eClinicalMedicinethelancet.com
- PubMedOrforglipron: A Comprehensive Review — Int J Mol Sci 2026 (PMID 41683830)pubmed.ncbi.nlm.nih.gov
- EMAICH E9(R1) — estimands in clinical trials (EMA)ema.europa.eu
- GuidelineGoogle — Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
Jack Muncaster · Founder, UK Peptides
Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.
More GLP-1 & Incretin Science articles
- How Many People Are Still Taking It a Year LaterTrials report what happens to people who stay on treatment. Real-world persistence with GLP-1 therapies is the variable that decides whether that matters.
- Why a Drug Works Less Well Than Its Trial SaidEfficacy is performance under trial conditions; effectiveness is what happens in practice. The gap is predictable, and it has identifiable causes.
- Why Weight Loss Can Restore OvulationObesity and insulin resistance disrupt ovulation, particularly in PCOS. Reversing them can restore fertility — which is a documented effect, not a rumour.
- Restored Fertility and Reduced Contraceptive AbsorptionOne effect makes conception more likely; another can reduce contraceptive protection. They act in the same population, and neither announces itself.
- When the Reason for Treatment Causes the OutcomePeople given a drug differ from those not given it — by the condition that prompted it. A 2026 Danish cohort shows the problem unusually clearly.
Popular across the research hub
One flagship guide from every other research category — keep exploring.
- Retatrutide ResearchHow One Peptide Engages Three Receptors
- GHK-Cu (Copper Peptide)GHK-Cu in the Published Literature
- TB-500 (Thymosin β4 fragment)BPC-157 and TB-500 Together: What the Evidence Says
- BPC-157 (Pentadecapeptide)BPC-157 Studied Effects, Sorted by Evidence
- CJC-1295 & IpamorelinStorage and Reconstitution for Both Compounds
- Peptide ReferenceEndotoxin: The Contaminant That Is Not a Protein
- Bacteriostatic WaterBacteriostatic Water for Reconstitution
- Research & Regulatory NewsCagriSema FDA Filing: Where the Review Stands
- MOTS-c (Mitochondrial Peptide)MOTS-c Storage, Stability and Reconstitution
- Semax (ACTH Fragment Peptide)Semax CAS Number and Chemical Identity
- Selank (Tuftsin Analogue)Selank Storage, Stability and Reconstitution
- DSIP (Delta Sleep-Inducing Peptide)What the Antibody Found in Peripheral Tissue
- KLOW (Blend)KLOW Regulatory Status
- GLOW (Blend)GLOW Regulatory Status
- MT-2 (Melanotan II)Alpha-MSH Engages Four of Five, Not All of Them
- IGF-1 LR3A Strong Rationale That Did Not Translate
- GlutathioneA Routine Liver Test That Measures a Glutathione Enzyme
- NAD+Two Products in This Catalogue, One Connected System
- KPVKPV Regulatory Status